1.14
NanoViricides Inc stock is traded at $1.14, with a volume of 49,688.
It is down -0.87% in the last 24 hours and down -4.20% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.15
Open:
$1.11
24h Volume:
49,688
Relative Volume:
0.18
Market Cap:
$17.83M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-1.6286
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
-5.79%
1M Performance:
-4.20%
6M Performance:
-19.15%
1Y Performance:
-10.94%
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NNVC
NanoViricides Inc
|
1.14 | 17.83M | 0 | -8.29M | -6.47M | -0.70 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
Virtu Financial LLC Acquires New Position in NanoViricides, Inc. (NYSE:NNVC) - Defense World
Small cap wrap: NanoViricides, G Mining Ventures, Nevis Brands... - Proactive Investors
NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative - Proactive Investors
NanoViricides Has Initiated Bio-analytical Studies as Part of IND-Enabling Safety and Toxicology Studies of Lead Candidate NV-HHV-101 - ACCESS Newswire
NanoViricides (NYSE:NNVC) Trading Up 1.7% – Time to Buy? - Defense World
Stock Update - Investorsobserver
AllPennyStocks.com News: Junior Biotech Bounces off $1; Chart Trying to Turn Bullish - ACCESS Newswire
Market movers: Delta, Kohl's, Asana, NanoViricides... - Proactive Investors UK
NanoViricides says business unaffected by US tariffs, highlights antiviral pipeline - Proactive financial news
Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments - Marketscreener.com
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company - Jonesboro Sun
Springing into action in time of need: NanoViricides, Inc. (NNVC.OB) - ACCESS Newswire
Unicycive Therapeutics Inc (NASDAQ:UNCY) stock: Is this a flash in the pan today? - US Post News
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan - Lelezard
NanoViricides' NV-387 could provide a crucial missing weapon in the fight against US measles outbreak - Proactive financial news
Investornewsbreaks Nanoviricides (NYSE American: NNVC) Highlights NV-387 As Potential Measles Treatment Amid Outbreak - MENAFN.COM
NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering - ACCESS Newswire
Mpox – a possible US$100mln+ opportunity - Proactive Investors USA
NanoViricides Successfully Completes Required Genetic Toxicology Testing of Lead Drug Candidate NV-HHV-101 - ACCESS Newswire
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am - ACCESS Newswire
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready - ACCESS Newswire
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2020Has Sufficient Cash, Progress on New Coronavirus Drug Program and the Lead HerpeCide(TM) Drug Candidate IND Application - ACCESS Newswire
NanoViricides Receives Cash Infusion of $2.25 Million - ACCESS Newswire
NanoViricides Closes on $8.625 Million Underwritten Public Offering of Common Stock - ACCESS Newswire
NanoViricides Has Initiated Required Safety Pharmacology Assessment of Lead Drug Candidate towards IND - ACCESS Newswire
Small cap headlines: EnWave, NanoViricides, GoviEx, TNR Gold... - Proactive Investors UK
NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials - Proactive Investors USA
NanoViricides, Inc. Has Filed its Quarterly Report - Chronicle-Tribune
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2024 - Marketscreener.com
NanoViricides Inc. (NNVC) reports earnings - Quartz
NanoViricides: Fiscal Q2 Earnings Snapshot - San Antonio Express-News
NanoViricides: Fiscal Q2 Earnings Snapshot -February 14, 2025 at 04:38 pm EST - Marketscreener.com
Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In? - Insider Monkey
7 Best Nanotech Penny Stocks to Invest In - Insider Monkey
NanoViricides announces readiness to combat bird flu with antiviral drug NV-387 - Proactive Investors UK
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape - Oil City Derrick
Powerful New Weapon Against Bird Flu: NanoViricides' Drug Outperforms Tamiflu in Lab Tests - StockTitan
NanoViricides Provides an Update on Its Clinical Program and StrategyNV-387 Could be As Revolutionary as Antibiotics - ACCESS Newswire
NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387 - Proactive Investors UK
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
NNVC’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts - Proactive Investors USA
NanoViricides (NYSE:NNVC) Trading Down 1.8% – What’s Next? - Defense World
NanoViricides to present at MicroCap Conference 2025 in Atlantic City - Proactive Investors Australia
Game-Changing Antiviral Drug Shows 'Superior Results' Against Multiple Viruses$10B Market Potential - StockTitan
NanoViricides advances antiviral drug with Phase II Clinical trial to Combat MPox - Proactive Investors USA
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):